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 Gas chromatography-mass spectrometry (GC-MS) is one of the most widely used 
instrumental techniques for chemical analyses in forensic science laboratories around the world 
due to its versatility and robustness. The most common type of chemical evidence submitted to 
forensic science laboratories is seized drug evidence, the analysis of which is largely dominated 
by GC-MS. Despite this, some drugs are difficult or impossible to analyze by GC-MS under 
normal circumstances. For these drugs, derivatization can be employed to make them more suitable 
for GC-MS.  
In Chapter 1, the derivatization of primary amino and zwitterionic drugs with three 
different derivatization agents, trifluoroacetic anhydride (TFAA); N,O-
bis(trimethylsilyl)trifluoroacetamide + 1% trimethylchlorosilane (BSTFA + 1% TMCS); and 
dimethylformamide dimethylacetal (DMF-DMA), is discussed. The chromatographic 
performance was quantified for comparison between the derivatives and their parent drugs. Peak 
symmetry was compared using the asymmetry factor (As), separation efficiency was measured by 
the number of theoretical plates (N), and sensitivity was compared by measuring the peak areas.  
In Chapter 2, derivatization techniques were adapted for an automated on-fiber 
derivatization procedure using a technique called total vaporization solid phase microextraction 
(TV-SPME). TV-SPME is a variation of SPME in which a small volume of sample solution is 
xii 
 
used which can be totally vaporized, removing the need to consider the equilibrium between 
analytes in the solution and analytes in the headspace. By allowing derivatization agent to adsorb 
to the SPME fiber prior to introduction to the sample vial, the entire derivatization process can 
take place on the fiber or in the headspace surrounding it. The use of a robotic sampler made the 
derivatization procedure completely automated.  
In Chapter 3, this on-fiber derivatization technique was tested on standards of 14 controlled 
substances as well as on realistic samples including simulated “street meth”, gamma-
hydroxybutyric acid (GHB) in mixed drinks, and hallucinogenic mushrooms, and was also tested 
on several controlled substances as solid powders. 
Future work in this area is discussed in Chapter 4, including adapting the method to 
toxicological analyses both in biological fluids and in hair. Some of the expected difficulties in 
doing so are discussed, including the endogenous nature of GHB in the human body. The presence 
of natural GHB in beverages is also discussed, which highlights the need for a quantitative addition 
to the method. Additional method improvements are also discussed, including proposed solutions 
for complete derivatization of more of the analytes, and for decreasing analysis time. 
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CHAPTER 1. TRADITIONAL DERIVATIZATION AND LIQUID 
INJECTION ANALYSIS 
Introduction 
A wide variety of controlled substances are submitted to forensic laboratories, making up 
a significant portion of all samples analyzed. However, some of these controlled substances are 
difficult to analyze by the typical means employed in forensic science laboratories. For example, 
Gas Chromatography-Mass Spectrometry (GC-MS) is a “workhorse” technique for drug chemistry 
units. However, not all drugs are amenable to GC-MS. For a substance to be analyzed by GC-MS, 
it must be volatile (i.e., exhibit a vapor pressure of at least one torr at the temperature of the GC 
inlet) and thermally stable (to at least 200 degrees Celsius). Additionally, some analytes exhibit 
poor chromatography due to non-ideal interactions with the stationary phase of the column. For 
example, zwitterions (which have at least one positively and one negatively charged functional 
group) and basic molecules such as amines are notorious for poor performance in gas 
chromatography. 
This chapter will discuss a portion of the work completed by Jordan Ash1, specifically the 
analysis and derivatization of several zwitterionic anti-epileptic drugs as well as primary amines, 
the structures of which are shown in Figure 1. 
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Amphetamine 
MW = 135 g/mol 
 
 
 
2C-I 
MW = 307 g/mol 
 
 
 
Gabapentin 
MW = 171 g/mol 
 
 
Pregabalin 
MW = 159 g/mol 
 
 
Clorazepate 
MW = 314 g/mol 
 
Lorazepam 
MW = 321 g/mol 
 
Vigabatrin 
MW = 129 g/mol 
 
Figure 1. Chemical structures of the drugs analyzed in this work 
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A common way to increase the volatility, thermal stability, and chromatographic 
performance of an analyte is via derivatization2. The process of derivatization replaces a labile 
hydrogen on the analyte molecule with a new functional group that increases the stability of the 
molecule.  Derivatives are most commonly formed via acylation, silyation and alkylation reactions. 
As shown in Figure 2, amine and hydroxylamine compounds can be derivatized via acylation, 
which is the replacement of a labile hydrogen with an acyl group3-4. Trifluoroacetic anhydride 
(TFAA) is a common acylation agent3, 5. In this reaction, the amine hydrogen is removed and 
replaced with a trifluoroacyl group. 
 
Figure 2. A generalized reaction between TFAA and a primary amine 
 
As shown in Figure 3, carboxylic and phosphonic acids can be derivatized by silylation, 
which is the replacement of a labile hydrogen with a trimethylsilyl group4, 6. N,O-
bis(trimethylsilyl)trifluoroacetamide (BSTFA) with trimethylchlorosilane (TMCS) is a commonly 
used silylating agent. Other silylation agents are available which attach larger silyl groups. For 
example, methyl-N-t-butyldimethylsilyltrifluoroacetamide (MTBSTFA) replaces labile 
hydrogens with t-butyldimethylsilyl groups. While MTBSTFA derivatives require more time to 
form, they are more stable7. 
4 
 
 
Figure 3. A generalized reaction with BSTFA where X is a nitrogen or an oxygen atom 
 
As shown in Figure 4, alkylation is the replacement of a labile hydrogen with an alkyl 
group4. Alkylation can be achieved through base- or acid-catalyzed transesterification using 
reagents such as KOH/methanol or H2SO4/methanol.  N,N-dimethylformamide dimethyl acetal 
(DMF-DMA) is an alkylation reagent that does not require catalysis and is compatible with most 
organic solvents. DMF-DMA has been used for the alkylation of fatty acids8, as well as the 
derivatization of amino acids9-10 and heterocyclic amines11. As shown in Figure 5, primary amines 
undergo Schiff base condensation, meaning that they lose 2 hydrogens, which are replaced with a 
dimethylaminomethylene (DMAM) group. A carbon-nitrogen double bond was thus formed, 
resulting in an imine9-11. In the case of amino acids, the carboxyl moiety is methylated as well, to 
form a methyl ester9-10. Though well known for those applications, the use of DMF-DMA for the 
derivatization of drugs of abuse has not been previously reported. 
 
Figure 4. A generalized reactionbetween DMF-DMA and a carboxylic acid 
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Figure 5. A generalized reaction between DMF-DMA and a primary amine 
 
As shown in Figure 6, chloroformates can be used to derivatize zwitterions. Although these 
reagents will not be discussed in this paper, ethyl chloroformate derivatives have been formed 
from pregabalin as a solid, in urine, and in pharmaceuticals12-13. Hexyl chloroformate derivatives 
have been formed from gabapentin, vigabatrin, and pregabalin in serum14.  
 
Figure 6. A generalized representation of chloroformate derivatization 
 
Spectrophotometric, spectrofluorometric, and liquid chromatographic methods have been 
reported for the identification of gabapentin, vigabatrin, and pregabalin15. Successful GC-MS 
analysis without derivatization has been reported for 2C-I in rat urine16, gabapentin in human 
serum17, and amphetamine18 and lorazepam19 in human urine. Amphetamine has been analyzed in 
hair20 and urine3, 21 using TFAA derivatization. N- N-methyl-bis(trifluoroacetamide) (MBTFA) 
has been used for the analysis of pure amphetamine samples5. 2C-I has been analyzed in rat urine 
using TFAA derivatization16. Gabapentin has been analyzed following derivatization with N-tert-
butyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA) in blood plasma and serum22. 
Lorazepam has been analyzed in urine utilizing both MTBSTFA derivatization23 and a dual 
derivatization procedure with MTBSTFA and TFAA24.  
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Despite these previous efforts, the reactions between several drugs and derivatization 
agents have not been explored.  For example, the use of DMF-DMA with these drugs has not been 
previously reported.  A summary of previous work in this area as well as those reactions that are 
reported here for the first time appears in Table 1. 
 
 
Table 1. References in which the zwitterions and primary amines presented in this work were 
successfully detected by GC-MS “as is” or using a derivatization agent of the category indicated.  
Reactions that were completed and will be discussed in this paper are also indicated. 
Drug Underivatized Acylation Silylation Alkylation 
Amphetamine n18 a3, 20-21, d5 b[This Work] c[This Work] 
2C-I n16 a16 b[This Work] c[This Work] 
Gabapentin n17 a[This Work] e22 c[This Work] 
Lorazepam n19 f24 e23 f24   c[This Work] 
Vigabatrin n[This Work] a[This Work] b[This Work] c[This Work] 
Pregabalin n[This Work] a[This Work] b[This Work] c[This Work] 
Clorazepate n[This Work] a[This Work] b[This Work] c[This Work] 
a = Trifluoroacetic anhydride (TFAA) 
b = N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) 
c = Dimethylformamide-dimethylacetal (DMF-DMA) 
d = N-Methyl-bis(trifluoroacetamide) (MBTFA) 
e = N-tert-Butyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA) 
f = Dual derivatization with TFAA and MTBSTFA 
n = none 
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Experimental 
Materials 
Gabapentin, vigabatrin, and 2C-I HCl were purchased from Cayman Chemical (Ann Arbor, 
Michigan). Lorazepam, pregabalin, amphetamine, dimethylformamide dimethyl acetal (DMF-
DMA) and trifluoroacetic anhydride (TFAA) were purchased from Sigma-Aldrich (St. Louis, 
Missouri). Clorazepate dipotassium was purchased from Grace Chemical (Columbia, Maryland). 
HPLC grade methanol, Optima acetonitrile, and N,O-bis(trimethylsilyl)trifluoroacetamide with 
1% trimethylchlorosilane (BSTFA + 1% TMCS) were purchased from Thermo Fisher Scientific 
(Waltham, Massachusetts).  
Sample Preparation 
The drug standards were dissolved in methanol at a concentration of 0.5 mg/mL. When 
samples were analyzed without derivatization, the solution in methanol was directly injected into 
the GC. Whenever derivatization was employed, additional sample preparation steps had to be 
taken. A volume of one milliliter of the methanolic drug solution was transferred to a GC 
autosampler vial. The methanol was then evaporated using a blow-down apparatus. Two hundred 
microliters of derivatization agent were then added to the vial and allowed to react at 60℃ until 
the solid had completely dissolved. Eight hundred microliters of acetonitrile were then added to 
bring the total volume back up to one milliliter before injection into the GC.  
GC-MS Parameters 
An Agilent 6890N GC coupled to an Agilent 5975 inert Mass Selective Detector with an 
attached Gerstel PAL RTC Multi-Purpose Sampler (MPS) was used for all experiments. The GC 
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column was an Agilent Technologies DB-5MS column with a length of 30 m, a 0.250 mm inner 
diameter, and a 0.25 µm film thickness. An injection volume of one microliter was used. 
The inlet temperature was set to 250°C and operated in split mode with a 15:1 ratio for 
amphetamine and in splitless mode for all other analytes. The initial oven temperature of 90°C was 
held for one minute, then the temperature was ramped at 15°C/min to 280°C where it was held for 
one minute. A speed optimized flow of 2.5 mL/min hydrogen was maintained. The mass transfer 
line was held at 280℃. The source was kept at 230°C and the quadrupoles were kept at 150°C. A 
scan range of m/z 40- m/z 550 was used. 
Results and Discussion 
Assessing Chromatographic Performance 
 Comparisons of chromatographic performance between underivatized drugs and their 
derivatives were desired for those drugs which were detected without derivatization. Peak 
symmetry, separation efficiency, and sensitivity were compared. Asymmetry factor (As) is 
calculated using equation 1, where b is the distance from the center of the peak to the tail edge of 
the peak at 10% peak height and a is the distance from the center of the peak to the front edge of 
the peak at 10% peak height. The closer As is to 1.0, the more symmetrical the peak. Conversely, 
values of As less than one indicate fronting while values greater than one indicate tailing. Percent 
improvement in symmetry was calculated using equation 2, where As
o is the asymmetry factor of 
the underivatized drug and As
1 is the asymmetry factor of the derivatized drug. 
 𝐴𝑠 =  𝑏 𝑎⁄  
 
(1) 
 
 |𝐴𝑠
𝑜 − 1| − |𝐴𝑠
1 − 1|
|𝐴𝑠
𝑜 − 1|
∗ 100% (2) 
 
 Separation efficiency was evaluated using the number of theoretical plates (N). The 
calculation for N is presented in equation 3, below, where tr is the retention time and W is the peak 
width. Percent increase in separation efficiency was calculated using equation 4, where No is the 
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number of theoretical plates for the underivatized drug and N1 is the number of theoretical plates 
for the derivatized drug. 
 
𝑁 = 16 (
𝑡𝑟
𝑊
)
2
 
 
(3) 
 
 𝑁1 − 𝑁𝑜
𝑁𝑜
∗ 100% (4) 
 
 Sensitivity was evaluated using peak areas, which were calculated by the auto-integration 
feature of the data analysis software. Percent increase in sensitivity was calculated using equation 
5, where Ao is the area under the curve for the underivatized drug and A1 is the area under the 
curve for the derivatized drug. 
 𝐴1 − 𝐴𝑜
𝐴𝑜
∗ 100% (5) 
 
Clorazepate 
Clorazepate was not detected in underivatized form. Analysis was also unsuccessful using 
TFAA derivatization due to the formation of multiple peaks which did not include the target 
derivative.  
BSTFA derivatization, however, produced a single chromatographic peak which was 
identified as the clorazepate-TMS derivative (see Figure 7). The derivative was not in the NIST 
library, but its structure was elucidated by its fragmentation pattern (see Figure 8). The amine 
group of clorazepate was preferentially silylated. Decarboxylation resulted in the m/z 45 and m/z 
341 ions. The latter ion exhibited an isotopic pattern confirming that one Cl atom was present.  
Cleavage of the TMS group resulted in the m/z 73 ion. Derivatization with DMF-DMA was 
unsuccessful for clorazepate as multiple peaks were formed, none of which was attributed to the 
expected derivative. 
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Figure 7. TIC of A: 0.5 mg/mL clorazepate derivatized with BSTFA + 1% TMCS, B: 0.5 mg/mL 
clorazepate in methanol. 
 
 
 
Figure 8. Structure and mass spectrum for clorazepate TMS. MW = 386 
 
Vigabatrin 
Vigabatrin was not detectable in the underivatized form and derivatization of vigabatrin 
with TFAA produced no results. 
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When silylated with BSTFA, a single chromatographic peak was produced (see Figure 9). 
This derivative was not in the NIST library, but its structure was elucidated by the fragmentation 
pattern (see Figure 11). Loss of a methyl group produced an [M-15]+ ion at m/z 186. From the m/z 
186 fragment, a loss of 17 was observed in the form of ammonia following hydrogen 
rearrangement 25. The base peak of m/z 56 was formed by alpha cleavage at the nitrogen. 
Derivatization with DMF-DMA produced a single chromatographic peak (see Figure 10). 
Vigabatrin underwent the same derivatization process with DMF-DMA as gabapentin. This 
derivative was not in the NIST library, but its structure was elucidated by the fragmentation pattern 
(see Figure 12). The molecular ion of m/z 198 was seen. The ion at m/z 167 was a result of the 
loss of the methoxy group, the base peak of m/z 111 was formed via alpha cleavage at the original 
nitrogen, and the m/z 154 ion was produced by alpha cleavage in the other direction losing the 
dimethylamine.  
 
Figure 9. TIC of A: 0.5 mg/mL vigabatrin derivatized with BSTFA + 1% TMCS, B: 0.5 mg/mL 
vigabatrin in methanol. 
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Figure 10. TIC of A: 0.5 mg/mL vigabatrin derivatized with DMF-DMA, B: 0.5 mg/mL vigabatrin 
in methanol. 
 
 
 
 
 
Figure 11. Structure and mass spectrum for vigabatrin TMS. MW = 201 
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Figure 12. Structure and mass spectrum for vigabatrin DMAM. MW = 198 
 
Pregabalin 
The results for pregabalin were generally negative.  The parent compound was not detected 
in the underivatized form. Derivatization using TFAA produced several chromatographic peaks, 
none of which were the expected derivative. The derivatization of pregabalin with BSTFA 
produced several peaks, including mono-, di-, and tri-TMS derivatives of pregabalin. Due to peaks 
for multiple products from one drug and a peak for underivatized pregabalin, the derivatization 
with BSTFA was considered unsuccessful. Derivatization with DMF-DMA also proved 
unsuccessful, with the target derivative detected but accompanied by multiple unidentified peaks. 
Amphetamine 
As expected, amphetamine could be identified without derivatization. It produced a single 
chromatographic peak with a mass spectrum that could be identified with a NIST mass spectral 
library search.  
Derivatization of amphetamine with TFAA produced a much larger, narrower, and more 
symmetric chromatographic peak compared to a solution of underivatized amphetamine at the 
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same concentration (see Figure 13). The TFA derivative of amphetamine was not in the NIST 
library, but the mass spectrum was easily identified by the fragmentation pattern (see Figure 15). 
The m/z 118 fragment resulted from McLafferty rearrangement with charge migration25. Alpha 
cleavage resulted in m/z 91 (tropylium) and a m/z 140 peak for the amine side chain.  
The reaction of amphetamine with BSTFA was not complete. The target compound 
(amphetamine-TMS) was formed and identified, but the underivatized form of the drug was still 
present in the sample. Several attempts were made to force the reaction to completion (e.g., 
increase in reagent concentration, increase in temperature for the reaction, increase in the amount 
of time allocated for the reaction to reach completion), but none were successful.  
Lastly, the reaction of amphetamine with DMF-DMA resulted in a product that has not 
been previously reported (see Figure 14). Amphetamine followed the same derivatization 
mechanism as heterocyclic amines with DMF-DMA (see Figure 16)11. There was no molecular 
ion seen in the mass spectrum, but alpha cleavage at the nitrogen originally present in amphetamine 
resulted in a fragment at m/z 91 (tropylium) and m/z 99, the base peak. The peak at m/z 44 was 
formed from alpha cleavage from that same nitrogen but cleaved after the carbon in the DMAM. 
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Figure 13. TIC of A: 0.5 mg/mL amphetamine derivatized with TFAA and B: 0.5mg/mL 
amphetamine in methanol. As = asymmetry factor. N = number of theoretical plates. 
 
 
Figure 14. TIC of A: 0.5 mg/mL amphetamine derivatized with DMF-DMA and B: 0.5 mg/mL 
amphetamine in methanol. As = asymmetry factor. N = number of theoretical plates. 
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Figure 15. Structure and mass spectrum for amphetamine TFA. MW = 231 
 
 
 
 
 
Figure 16. Structure and mass spectrum of amphetamine DMAM. MW = 190 
 
2C-I 
Like amphetamine, 2C-I was detected without derivatization, producing a single 
chromatographic peak with a mass spectrum that was identified with a NIST mass spectral library 
search. 
The reaction of TFAA with 2C-I also resulted in a taller and narrower peak than that 
produced by underivatized 2C-I (see Figure 17). The 2C-I TFA derivative was not in the NIST 
0
10
20
30
40
50
60
70
80
90
100
0 50 100 150 200 250 300
R
el
at
iv
e 
A
b
u
n
d
an
ce
m/z
140118
91
69
0
10
20
30
40
50
60
70
80
90
100
0 50 100 150 200 250 300
R
el
at
iv
e 
A
b
u
n
d
an
ce
m/z
99
9144
117
17 
 
library, but the structure was elucidated by its fragmentation pattern (see Figure 19). After 
derivatization with TFAA, 2C-I had a molecular ion at m/z 403. The ion at m/z 290 was the result 
of McLafferty rearrangement with charge migration25. The molecular ion underwent alpha 
cleavage at the nitrogen, which produced a fragment at m/z 277 and a fragment at m/z 126. The 
fragment at m/z 247 was a result of cleavage of two methyl groups from the m/z 277 fragment. 
Derivatization with BSTFA yielded both a 2C-I derivative with one TMS group on the 
primary nitrogen and a derivative with two TMS groups on the primary nitrogen. Due to the 
formation of two derivatives from one analyte, this reaction was determined to be unsatisfactory. 
Derivatization of 2C-I with DMF-DMA was, as with amphetamine, a new approach that 
produced a novel product (see Figure 18). Just like amphetamine, the labile hydrogens on the 
primary amine in 2C-I were replaced with a DMAM group (see Figure 20). The same alpha 
cleavage paths resulted in the base peak of m/z 85 and the characteristic m/z 44. There was no 
molecular ion seen in 2C-I, however there was a small ion at m/z 331. This fragment was a result 
of the molecular ion losing 31 mass units (methoxy) from the aromatic ring. 
 
Figure 17. TIC of A: 0.5 mg/mL 2C-I derivatized with TFAA and B: 0.5 mg/mL 2C-I in methanol. 
As = asymmetry factor. N = number of theoretical plates. 
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Figure 18. TIC of A: 0.5 mg/mL 2C-I derivatized with DMF-DMA and B: 0.5 mg/mL 2C-I in 
methanol. As = asymmetry factor. N = number of theoretical plates. 
  
 
 
 
 
Figure 19. Structure and mass spectrum for 2C-I TFA. MW = 403 
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Figure 20. Structure and mass spectrum of 2C-I DMAM. MW = 362 
 
Gabapentin 
Although potentially problematic for GC-MS analysis, underivatized gabapentin produced 
a single chromatographic peak with a mass spectrum that was identified with a NIST mass spectral 
library search. After ionization, gabapentin underwent a loss of water resulting in an ion at m/z 
154. The remaining structure cyclized via hydrogen rearrangement prior to the cleavage of the 
cycloalkane. The low mass ions seen in the mass spectrum were characteristic of the fragmentation 
of cycloalkanes. 
Derivatization with TFAA produced a single chromatographic peak (Figure 21). This 
derivative was not in the NIST library, but its mass spectrum was identified by analyzing the 
fragmentation pattern (see Figure 23). One of the hydrogens on the amine nitrogen was replaced 
by a trifluoroacetyl group. The molecular ion was not seen on the mass spectrum. Instead, an M-
18 (m/z 249) peak was seen arising from the loss of water. The m/z 180 base peak was formed by 
the further loss of CF3. 
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Derivatization of gabapentin with BSTFA was not successful. No target derivative was 
formed. Derivatization of gabapentin by DMF-DMA produced a single chromatographic peak (see 
Figure 22). This derivative was not in the NIST library, but its mass spectrum was identified by 
analyzing the fragmentation pattern (see Figure 24). Gabapentin contains both a primary amine 
and a carboxylic acid, so its derivatization was directly analogous to that of primary amino acids9. 
The amine underwent the same process as that in amphetamine and 2C-I, and the carboxylic acid 
was methylated in one step, resulting in an N,N-dimethylaminomethylene methyl ester9. The 
molecular ion (m/z 240) was seen in very small abundance in the mass spectrum.  A fragment was 
seen at m/z 209 which was the result of the molecular ion losing 31 mass units in the form of a 
methoxy radical. The base peak of m/z 85 resulted from alpha cleavage at the original nitrogen. 
Loss of the dimethylamino group resulted in an m/z 44 and an m/z 196 fragment. 
 
Figure 21.  TIC of A: 0.5 mg/mL gabapentin derivatized with TFAA and B: 0.5 mg/mL gabapentin 
in methanol. As = asymmetry factor. N = number of theoretical plates. 
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Figure 22.  TIC of A: 0.5 mg/mL gabapentin derivatized with DMF-DMA and B: 0.5 mg/mL 
gabapentin in methanol. As = asymmetry factor. N = number of theoretical plates. 
 
 
 
Figure 23. Structure and mass spectrum for gabapentin TFA. MW = 267 
 
4 5 6 7 8 9 10 11 12 13 14
T
IC
TIME (min)
A
B
As = 0.24   N = 3.2 x 10
5
As = 1.158
N = 1.6 x 106
0
10
20
30
40
50
60
70
80
90
100
0 50 100 150 200 250 300
R
el
at
iv
e 
A
b
u
n
d
an
ce
m/z
180
249
22 
 
 
 
 
Figure 24. Structure and mass spectrum for gabapentin DMAM. MW = 240 
 
Lorazepam 
Despite some concerns about the analysis of lorazepam by GC/MS, it produced a single 
chromatographic peak that was identified with a NIST library search. The mass spectrum of 
lorazepam had a low mass ion series that was indicative of aromatic compounds (e.g., m/z 50, 51, 
63, 64, 74, 75, and 76)25. This most likely arose from fragmentation of the aromatic ring following 
the alpha cleavage from the nitrogen. A fragment of m/z 302 corresponded to a loss of 20 amu 
from the molecular ion. The isotopic signature of chlorine was used to determine the number of 
chlorines in each ion25. Because 37Cl is present at about one third the abundance of 35Cl in nature, 
an ion two mass units heavier than the target ion with one third the abundance of the target ion 
indicates the presence of one chlorine in the target fragment while an ion two mass units heavier 
than the target ion with two thirds the abundance indicates the presence of two chlorines. Given 
this, it was determined that the loss of one chlorine radical from the m/z 302 fragment resulted in 
a fragment of m/z 267, the loss of 28 from the m/z 302 fragment resulted in a fragment at m/z 274, 
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and the loss of both a chlorine and an additional 28 mass units from the m/z 302 fragment resulted 
in the base peak at m/z 239. 
Derivatization with TFAA was unsuccessful as no derivative was detected. Derivatization 
with BSTFA produced a single chromatographic peak with a mass spectrum that was identified as 
the di-TMS derivative of lorazepam by a NIST library search. The base peak at m/z 429 results 
from the loss of a chlorine radical.  
DMF-DMA derivatization was unsuccessful with lorazepam due to the formation of 
multiple peaks which could not be attributed to the target derivative. 
 
Figure 25.  TIC of A: 0.5 mg/mL lorazepam derivatized with BSTFA + 1% TMCS and B: 0.5 
mg/mL lorazepam in methanol. As = asymmetry factor. N = number of theoretical plates 
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Figure 26. Structure and mass spectrum for lorazepam TMS. MW = 464 
 
As shown in Tables 2 – 4, chromatographic performance was greatly improved through 
derivatization. For example, the peak asymmetry for amphetamine improved by 47% with the 
DMAM derivative and 98% with the TFA derivative. In addition, separation efficiency increased 
by 1,355% for the DMAM derivative and 1,047% for the TFA derivative. Sensitivity increased by 
1,220% for the DMAM derivative and 533% for the TFA derivative. The peak asymmetry for 2C-
I improved by 55% with the DMAM derivative and 9% with the TFA derivative. Separation 
efficiency for 2C-I increased by 406% for the DMAM derivative and 279% for the TFA derivative. 
The sensitivity decreased by 86% for the DMAM derivative and increased by 118% for the TFA 
derivative. The peak asymmetry for gabapentin improved by 79% with the DMAM derivative and 
92% with the TFA derivative. Separation efficiency was also increased by 393% for the DMAM 
derivative and 403% for the TFA derivative. Sensitivity for gabapentin was increased by 63% for 
the DMAM derivative and decreased by 91% for the TFA derivative. The peak asymmetry for 
lorazepam improved by 96% with the TMS derivative. Separation efficiency was increased by 
119%, and sensitivity was increased by 64%. 
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Table 2. Comparing asymmetry factors for underivatized drugs and their derivative(s) 
Drug Underivatized TFA TMS DMAM 
Amphetamine 8.5 0.86 - 5.0 
2C-I 1.7 0.33 - 1.3 
Gabapentin 0.24 0.94 - 1.2 
Lorazepam 10.5 - 0.67 - 
 
Table 3. Comparing separation efficiency (number of theoretical plates) for underivatized 
drugs and their derivative(s) 
Drug Underivatized (/106) TFA (/106) TMS (/106) DMAM (/106) 
Amphetamine 0.12 1.4 - 1.8 
2C-I 0.7 2.7 - 3.5 
Gabapentin 0.32 1.6 - 1.6 
Lorazepam 2.8 - 6.2 - 
 
Table 4. Comparing sensitivity (peak area) for underivatized drugs and their derivative(s) 
Drug Underivatized (/107) TFA (/107)  TMS (/107) DMAM (/107) 
Amphetamine 1.1 6.8 - 14 
2C-I 42 91 - 5.7 
Gabapentin 68 6.0 - 110 
Lorazepam 7.2 - 12 - 
 
Conclusions 
 Basic and zwitterionic drugs can be amongst the most difficult to analyze via GC/MS due 
to their thermal instability and non-ideal behavior resulting in broad, asymmetric peaks. A 
summary of the drugs and derivatizations discussed in this paper appears in Table 5.  
 
Table 5. A summary of the results of this work. + indicates the formation of a single 
chromatographic peak which could be unambiguously identified. – indicates no relevant peak 
was formed. 0 indicates multiple peaks were formed. 
Drug Underivatized TFAA BSTFA DMF-DMA 
Amphetamine + + 0 + 
2C-I + + 0 + 
Gabapentin + + - + 
Lorazepam + - + - 
Vigabatrin - - + + 
Pregabalin - - 0 0 
Clorazepate - - + - 
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Amphetamine, 2C-I, gabapentin, and lorazepam were successfully analyzed by GC/MS 
without modification.  However, the number of theoretical plates achieved was dramatically 
increased by derivatization and peak symmetry was greatly improved. Direct GC/MS analysis of 
vigabatrin, pregabalin and clorazepate yielded negative results, as no peaks were formed. 
Among the drugs of interest, amphetamine and 2C-I were readily derivatized with TFAA.  
The derivatives produced more intense and narrower chromatographic peaks than their 
underivatized forms. Gabapentin was also successfully derivatized with TFAA, but the resulting 
chromatographic peak was smaller in magnitude than that of the underivatized drug. Lorazepam, 
vigabatrin, pregabalin, and clorazepate were not successfully derivatized by TFAA – lorazepam 
and vigabatrin produced no chromatographic peaks, while pregabalin and clorazepate both 
produced multiple peaks, none of which were the target derivatives. 
Derivatization with BSTFA + 1% TMCS produced single chromatographic peaks for 
lorazepam, vigabatrin, and clorazepate. The derivatization was incomplete for amphetamine and 
wholly unsuccessful for gabapentin, producing no derivative. BSTFA derivatization yielded 
multiple derivatives with one, two, or even three TMS groups for 2C-I and pregabalin. 
As previously discussed, methyl-N-t-butyldimethylsilyltrifluoroacetamide (MTBSTFA) 
and other silylation reagents that replace active hydrogens with larger t-butyldimethylsilyl rather 
than trimethylsilyl groups generally take longer to form, but are more stable. Additionally, the t-
butyldimethylsilyl group is more sterically hindering than the trimethylsilyl group, so t-
butyldimethylsilyl reagents will likely form only one derivative with primary amines. It is 
therefore possible that reactions with BSTFA that were unsuitable due to multiple products or for 
which no derivative was detected here may produce useful results when reacted with larger 
silylation reagents such as MTBSTFA. 
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Lastly, DMF-DMA proved an effective new method for the derivatization of the primary 
amines amphetamine, 2C-I, gabapentin, and vigabatrin. The primary amine hydrogens in 
amphetamine and 2C-I were replaced with a DMAM group. Gabapentin and vigabatrin, containing 
both a primary amine and a carboxyl group, underwent the addition of a methyl group and a 
DMAM group. Derivatization with DMF-DMA did not yield favorable results for lorazepam, 
pregabalin, or clorazepate. As previously discussed, the derivative for pregabalin was formed, but 
there were several other peaks present in the chromatogram that could not be identified. The 
chromatograms for both lorazepam and clorazepate showed multiple peaks, none of which could 
be attributed to the target derivatives. 
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CHAPTER 2. DEVELOPMENT OF TV-SPME ON-FIBER 
DERIVATIZATION OF CONTROLLED SUBSTANCES 
Introduction 
Derivatization has long been used to improve the characteristics of controlled substances 
that are not sufficiently volatile and/or thermally unstable during GC-MS analysis.  By derivatizing 
these compounds, the chromatographic performance is significantly improved2. Chapter 1 
demonstrated the effectiveness of traditional liquid derivatization techniques coupled with liquid 
injection GC-MS methods for several controlled substances.  
 Derivatization offers many benefits, but traditional solution phase techniques are work 
intensive and time consuming. However, derivatization can be adapted to a sampling technique 
developed by our laboratory called Total Vaporization Solid-Phase Microextraction (TV-SPME) 
to simplify and automate the process. Solid-Phase Microextraction (SPME) is a technique in which 
the analytes are pre-concentrated onto a fiber coated in absorptive or adsorptive material. TV-
SPME is a novel technique in which a small aliquot of solution is placed in a vial and heated until 
the sample completely vaporizes26-27. A SPME fiber is then introduced and the sample is adsorbed 
onto the fiber coating. TV-SPME is analogous to immersion SPME in that both are two-phase 
systems unlike headspace SPME, which is a three-phase system. 
 The maximum volume for total vaporization of a given solvent can be easily calculated 
given the solvent vapor pressure, molecular weight, vial volume and temperature26. For example, 
the calculated maximum volume of methanol for total vaporization in a 20-mL vial at 60°C is 24 
µL.  
The use of TV-SPME for sampling can streamline the process of derivatization by allowing 
it to be done simultaneously with the extraction step in a process called on-fiber derivatization. 
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On-fiber derivatization has been used before in conjunction with headspace or immersion SPME3, 
28-31. It would be desirable, however, to bring the advantages offered by TV-SPME to bear for on-
fiber derivatization. In on-fiber derivatization with TV-SPME, a SPME fiber is exposed to the 
headspace of a vial containing a small amount of liquid derivatization agent.  The fiber is then 
moved to the heated headspace of a vial containing the sample. The reaction between the analyte 
and the derivatization agent then takes place directly on the SPME fiber or in the headspace 
surrounding the fiber. After sufficient time for reaction and adsorption, the fiber is moved to the 
inlet of the GC for desorption. The use of a robotic autosampler can make this a fully automated 
process wherein the only sample prep necessary is to dissolve the sample in a suitable solvent and 
place an aliquot into the vial. 
 
Figure 27. Depiction of the On-Fiber Total Vaporization Solid-Phase Microextraction process. 
 
The controlled substances chosen for this project were a combination of drugs commonly 
encountered in forensic laboratories and drugs that are difficult or impossible to analyze “as is” by 
traditional GC-MS methods. The structures and molecular weights of the chosen drugs are 
displayed in figures 28 and 29, below. 
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Amphetamine 
MW = 135 g/mol 
LogPow = 1.76 
 
 
 
Methamphetamine 
MW = 149 g/mol 
LogPow = 2.22 
 
Ephedrine 
MW = 165 g/mol 
LogPow = 0.68 
 
 
2C-I 
MW = 307 g/mol 
LogPow = 2.67 
 
 
 
25I-NBOMe 
MW = 427 g/mol 
LogPow = 4.92 
 
 
25I-NBOH 
MW = 413 
LogPow = 4.36 
 
 
Gamma-hydroxybutyric acid (GHB) 
MW = 104 g/mol 
LogPow = -0.4 
 
Figure 28. Structures, molecular weights, and octanol:water partition coefficient (LogPow) of the 
drugs analyzed in this work. 
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Psilocin 
MW = 204 g/mol 
LogPow = 1.46 
 
 
Psilocybin 
MW = 284 g/mol 
LogPow = 1.00 
 
 
Gamma-hydroxybutyric acid (GHB) 
MW = 104 g/mol 
LogPow = -0.4 
 
 
Gabapentin 
MW = 171 g/mol 
LogPow = -1.10 
 
 
Clorazepate 
MW = 314 g/mol 
LogPow not found 
 
Lorazepam 
MW = 321 g/mol 
LogPow = 3.98 
 
 
Vigabatrin 
MW = 129 g/mol 
LogPow = -2.16 
 
 
Pregabalin 
MW = 159 g/mol 
LogPow = -1.78 
Figure 29. Structures, molecular weights, and octanol:water partition coefficient (LogPow) of the 
zwitterionic drugs analyzed in this work. 
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Experimental 
Materials 
Amphetamine sulfate, methamphetamine HCl, ephedrine HCl, lorazepam, pregabalin, and 
dimethylformamide dimethyl acetal (DMF-DMA) were purchased from Sigma-Aldrich (St. Louis, 
Missouri). Psilocybin, psilocin, 4-iodo-2,5-dimethoxy-β-phenethylamine (2C-I) hydrochloride, 4-
iodo-2,5-dimethoxy-N-(2-methoxybenzyl) phenethylamine (25I-NBOMe) hydrochloride, 2-[[2-
(4-iodo-2,5 dimethoxyphenyl) ethylamino] methyl] phenol  (25I-NBOH) hydrochloride, gamma-
hydroxybutyric acid (GHB), gabapentin, and vigabatrin were purchased from Cayman Chemical 
(Ann Arbor, Michigan).  Clorazepate dipotassium was purchased from Grace Chemical 
(Columbia, Maryland). HPLC grade methanol, Optima acetonitrile, stabilized HPLC grade 
methylene chloride, trifluoroacetic anhydride (TFAA), and N,O-
bis(trimethylsilyl)trifluoroacetamide with 1% trimethylchlorosilane (BSTFA + 1% TMCS) were 
purchased from Thermo Fisher Scientific (Waltham, Massachusetts). Polydimethyl siloxane solid 
phase microextraction fibers, 100 µm film thickness, were purchased from Supelco (Bellefonte, 
Pennsylvania). 
Sampling Method 
Standard solutions of all drugs were prepared in methanol at a concentration of 1 mg/mL, 
except for GHB, gabapentin, and vigabatrin, which were at a concentration of 0.6 mg/mL.  For 
underivatized drugs, 24 µL of each drug solution in methanol was dispensed into a 20-mL 
headspace vial for analysis. The SPME fiber was exposed to the contents of the vial, which was 
heated with agitation to 30, 60, 90, 120, 150, 180, or 200°C, for 15 minutes before moving to the 
inlet of the GC for desorption at 250℃. 
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 For derivatization, 24 µL of drug solution in methanol were dispensed into a 20-mL 
headspace vial and the solvent was evaporated. 18 µL of acetonitrile were then added to the vial. 
A new vial containing fresh derivatization agent (TFAA, BSTFA +1% TMCS, or DMF-DMA) 
was prepared at the beginning of each day. The derivatization agent used for each drug was 
determined by previous work done with liquid-phase derivatization in our laboratory. Amine and 
hydroxylamine drugs were designated for derivatization with TFAA. Psilocin and psilocybin were 
designated for derivatization with both TFAA and BSTFA + 1% TMCS. GHB was designated for 
derivatization with BSTFA + 1% TMCS. The zwitterionic drugs were designated for derivatization 
with both BSTFA + 1% TMCS and DMF-DMA. The SPME fiber was exposed to the headspace 
of the derivatization vial for five minutes, then exposed to the drug vial, which was heated with 
agitation at the optimum temperature found for the underivatized drug, for 10 minutes before 
moving to the inlet of the GC for desorption at 250℃. The fiber was cleaned by heating it in the 
second inlet of the GC at 250°C for 10 minutes after each derivatization run. 
GC-MS Parameters 
An Agilent 6890N GC coupled to an Agilent 5975 inert Mass Selective Detector with an 
attached Gerstel PAL RTC MultiPurpose Sampler (MPS) was used for all experiments. The GC 
column was an Agilent Technologies DB-5MS column with a length of 30 m, a 0.250 mm inner 
diameter, and a 0.25 µm film thickness. Straight inlet liners of 1.2 mm inner diameter from SGE 
Analytical Science were used. This type of inlet liner was chosen because the vapor volume 
introduced in derivatization runs was too great for 0.75 mm inner diameter SPME-specific inlet 
liners, resulting in split peaks and “echo” effects for derivatives and derivatization agents. 
The inlet temperature was set to 250°C and operated in split mode with a 15:1 split ratio. The 
initial oven temperature of 60°C was held for one minute, then the temperature was ramped at 
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15°C/min to 280°C where it was held for three minutes. A constant flow of 2.5 mL/min of 
hydrogen was maintained. The source was kept at 230°C and the quadrupoles were kept at 150°C. 
A scan range of m/z 40- m/z 550 was used, with a solvent delay of 2 minutes. 
Results 
Extraction Temperature Study 
Each drug was analyzed “as is” with extraction temperatures ranging from 30°C to 200°C 
to determine the optimum temperature. Figures 30-32 illustrate the effect of extraction temperature 
on analyte signal for those drugs that were detected in the underivatized form by TV-SPME. The 
optimum extraction temperature was then chosen as the starting extraction temperature for on-
fiber derivatization. When the boiling point of each analyte is plotted against its experimentally 
determined optimum extraction temperature, a trend is revealed. The coefficient of determination 
(R2) describes how well the regression line represents the data. For this data set R2 = 0.6892, 
indicating that the predicting power of the regression line is rather low. The correlation coefficient 
(r) is a measure of how closely the two variables, in this case boiling point and optimum extraction 
temperature, are correlated. For this data set r = 0.8302, indicating that there is a modest but 
significant correlation between an analyte’s boiling point and its optimum extraction temperature. 
Taken together, the correlation coefficient and coefficient of determination tell us that boiling point 
and optimum extraction temperature are correlated, but that not all of the variation in optimum 
extraction temperature can be explained by boiling point alone. The plot of optimum extraction 
temperature vs. boiling point is shown in Figure 33. 
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Figure 30. Graph of peak area vs extraction temperature for underivatized phenethylamines. Peak 
area was calculated using the extracted ion profile (EIP) for the ion indicated. 
 
 
Figure 31. Graph of peak area vs extraction temperature for underivatized designer drugs. Peak 
area was calculated using the extracted ion profile (EIP) for the ion indicated. 
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Figure 32. Graph of peak area vs extraction temperature for underivatized zwitterions. Peak area 
was calculated using the extracted ion profile (EIP) for the ion indicated. 
 
 
Figure 33. Graph of experimentally determined optimum extraction temperature vs known boiling 
point for underivatized drugs. 
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Amphetamine 
 Amphetamine was detected in the underivatized form, with 60℃ being the optimum 
extraction temperature. It produced a single chromatographic peak which could be identified with 
a NIST mass spectral library search. A single chromatographic peak which corresponded to the 
amphetamine TFA derivative was produced when amphetamine was derivatized with TFAA on-
fiber. This peak was slightly overloaded, causing some mild fronting. The derivative was not found 
in the NIST mass spectral library, but was identified by its fragmentation pattern, the interpretation 
of which was discussed in chapter 1. See equations 1-5 in chapter 1 for the calculation of 
asymmetry factor, number of theoretical plates, sensitivity, and their respective percent 
improvements. 
 
Figure 34. TIC of A: 24 µg of amphetamine in 18 µL of acetonitrile derivatized with TFAA, B: 
24 µg of amphetamine in 24 µL of methanol. As = asymmetry factor, N = number of theoretical 
plates. 
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Methamphetamine 
 Methamphetamine was detected in the underivatized form but exhibited exceedingly poor 
chromatographic behavior and many extraneous chromatographic peaks. It was identified by a 
NIST mass spectral library search. On-fiber derivatization with TFAA produced a single 
chromatographic peak which was identified with a NIST mass spectral library search as well. 
 
Figure 35. TIC of A: 24 µg of methamphetamine in 18 µL of acetonitrile derivatized with TFAA, 
B: 24 µg of methamphetamine in 24 µL of methanol. As = asymmetry factor, N = number of 
theoretical plates. 
 
 
 
 
 
 
 
  
 
Figure 36. Structure and mass spectrum for methamphetamine TFA. MW = 245 
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Ephedrine 
 Ephedrine was detected in the underivatized form, with an optimum extraction temperature 
of 90℃. A single chromatographic peak was produced, aside from low-abundance background 
siloxanes, which was identified with a NIST mass spectral library search. However, derivatization 
on-fiber with TFAA was unsuccessful. Though the derivative was formed, the signal was much 
lower than that of the drug when underivatized and many siloxanes were present in the 
chromatogram at greater abundance than the derivative. The ephedrine TFA derivative was 
identified by liquid injection using traditional solution-phase derivatization in previous work in 
our laboratory1, as well as by others32-34. Furthermore, as will be discussed in chapter 3, successful 
identification of the ephedrine TFA derivative, with excellent signal, was achieved using solid 
ephedrine powder with a much greater sample mass (1 mg). It is possible that the problem stems 
from the fact that ephedrine is the most hydrophilic of the phenethylamines analyzed (LogPo/w = 
0.68), but there are too many variables to know exactly why this is happening without further 
experimentation. 
 
Figure 37. TIC for 24 µg of ephedrine in 24 µL of methanol. 
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2C-I 
 2C-I was detected in the underivatized form, with an optimum extraction temperature of 
120℃. It produced a single chromatographic peak which could not be identified with a NIST mass 
spectral library search, but was identified by its fragmentation pattern, as has been previously 
reported16. A single chromatographic peak for 2C-I TFA was produced when 2C-I was derivatized 
with TFAA on-fiber. This derivative was not found in the NIST mass spectral library, but was 
identified by its fragmentation pattern, the interpretation of which was discussed in chapter 1. 
 
Figure 38. TIC of A: 24 µg of 2C-I in 18 µL of acetonitrile derivatized with TFAA, B: 24 µg of 
2C-I in 24 µL of methanol. As = asymmetry factor, N = number of theoretical plates. 
 
25I-NBOMe 
 This drug was detected without derivatization, with an optimum extraction temperature of 
180℃. A single chromatographic peak was produced, which could not be found in the NIST mass 
spectral library, but which could be identified by its fragmentation pattern. Initial alpha cleavage 
at the nitrogen produced a fragment with m/z 150. Another fragment with m/z 150 could have 
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formed with the loss of iodine from the larger fragment after alpha cleavage. A further loss of 
CNH3 radical from this fragment yields an ion with m/z 121, the base peak
25 
A single chromatographic peak for the 25I-NBOMe TFA derivative was produced by on-
fiber derivatization with TFAA. The derivative was not found in the NIST mass spectral library 
but could be identified by its fragmentation pattern. The derivative had a molecular ion at m/z 523. 
Alpha cleavage at the nitrogen resulted in a fragment with m/z 277. The side chain fragment then 
cleaved at the nitrogen, resulting in a fragment which consisted of an aromatic ring with a methoxy 
and a methylene group, m/z 121. 
 
Figure 39. TIC of A: 24 µg of 25I-NBOMe in 18 µL of acetonitrile derivatized with TFAA, B: 24 
µg of 25I-NBOMe in 24 µL of methanol. As = asymmetry factor, N = number of theoretical plates. 
 
8 10 12 14 16 18
T
IC
TIME (MIN)
B
A
As = 0.25
N = 3.4 x 106
As = 0.31
N = 2.1 x 106
42 
 
 
 
 
 
 
 
Figure 40. Fragmentation diagram and mass spectrum, underivatized 25I-NBOMe. MW = 427 
 
 
 
 
 
Figure 41. Fragmentation diagram and mass spectrum of 25I-NBOMe TFA. MW = 523 
 
25I-NBOH 
25I-NBOH was detected without derivatization at an extraction temperature of 180℃. The 
target compound was only present as a poorly shaped peak with low abundance. The 
chromatogram was dominated by the peak for 2C-I, which 25I-NBOH is known to convert to in 
the heated GC inlet. The detection of 25I-NBOH by GC-MS has not been reported. The mass 
spectrum was not present in the NIST library, but it could be identified by its fragmentation pattern. 
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Upon ionization, 25I-NBOH lost the two labile hydrogens from the amine and hydroxyl groups. 
Subsequent alpha cleavage on the side of the nitrogen closest to the iodine resulted in a fragment 
with m/z 277 and another with m/z 134. 
The chromatographic peak for the 25I-NBOH derivative was not the only peak produced 
by on-fiber derivatization of 25I-NBOH with TFAA. A peak for 2C-I was present as well as several 
unidentified peaks, but 25I-NBOH TFA was the most prominent peak in the chromatogram. The 
derivative was not found in the NIST mass spectral library but could be identified by its 
fragmentation pattern. The derivative had a molecular ion of m/z 509. The hydrogen of the 
hydroxyl group could be lost, which was necessary to produce the m/z 107 peak. Alpha cleavage 
at the nitrogen produced a fragment with m/z 277. McLafferty rearrangement with charge 
migration25 resulted in the fragment with m/z 290. 
 
Figure 42. TIC of A: 24 µg of 25I-NBOH in 18 µL of acetonitrile derivatized with TFAA, B: 24 
µg of 25I-NBOH in 24 µL of methanol. As = asymmetry factor, N = number of theoretical plates. 
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Figure 43. Fragmentation diagram and mass spectrum of underivatized 25I-NBOH. MW = 413 
 
 
 
 
 
Figure 44. Fragmentation diagram and mass spectrum for 25I-NBOH TFA. MW = 509 
 
Psilocin 
 Psilocin was detected in the underivatized form, with 90℃ being the optimum extraction 
temperature. It produced a single chromatographic peak which could be identified with a NIST 
mass spectral library search. However, derivatization with TFAA was unsuccessful. BSTFA + 1% 
TMCS derivatization was successful with psilocin, though incomplete. There remained a small 
chromatographic peak for underivatized psilocin, but the psilocin TMS peak dominated the 
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chromatogram. It is suspected that this derivatization could be brought to completion by exposing 
the fiber to the derivatization agent for a longer time or by increasing the extraction time. The mass 
spectrum for the derivative was not in the NIST library, but it was identified using its fragmentation 
pattern. The molecular ion is present at m/z 276. Alpha cleavage at the nitrogen resulted in 
fragments at m/z 218 and m/z 58. The TMS group, which is present in all TMS derivatives, is the 
fragment at m/z 73. 
 
Figure 45. TIC of A: 24 µg of psilocin in 18 µL of acetonitrile derivatized with BSTFA + 1% 
TMCS, B: 24 µg of psilocin in 24 µL of methanol. As = asymmetry factor, N = number of 
theoretical plates. 
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Figure 46. Fragmentation diagram and mass spectrum for psilocin TMS. MW = 276 
 
Psilocybin 
 Psilocybin was not detected by TV-SPME either with or without derivatization. No peaks 
were formed that could be identified as either psilocybin or one of its derivatives. 
 
GHB 
 Gamma-hydroxybutyric acid could not be detected without derivatization due to its low 
volatility and poor thermal stability. Derivatization with BSTFA + 1% TMCS resulted in a single 
peak for GHB di-TMS. Derivatization replaced both hydroxyl hydrogens with TMS groups. This 
derivative was identified by a NIST mass spectral library search. As is common with TMS 
derivatives, the molecular ion was not present. An [M-15]+ fragment, formed by the loss of a 
methyl from the TMS group, was present at m/z 233 and can be used as an ion indicative of GHB 
di-TMS. Cleavage of the carbon chain formed an m/z 117 fragment. The fragment m/z 73, which 
corresponds to a single TMS group, is very common in TMS derivatives. Among derivatives with 
multiple TMS ether groups close together, m/z 147 is also a very common fragment as it 
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corresponds to a TMS group bonded to an oxygen which is bonded to a dimethylsilyl group28. This 
forms the base peak in the mass spectrum of GHB di-TMS. 
 
Figure 47. TIC of A: 14.4 µg of GHB in 18 µL of acetonitrile derivatized with BSTFA + 1% 
TMCS, B: 14.4 µg of GHB in 24 µL of methanol. 
 
 
 
 
 
 
Figure 48. Structure and mass spectrum of GHB di-TMS. MW = 248 
 
Gabapentin 
In the liquid injection method, underivatized gabapentin produced a single 
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search. The same was true of underivatized gabapentin using the TV-SPME method with an 
extraction temperature of 120℃. The peak exhibits fronting, which indicates that the column was 
overloaded with sample. The Langmuir adsorption model treats the stationary phase as a single 
solid layer with a finite number of active sites. When a sample introduction overloads the column 
and all of the sites at the head of the column are filled with analyte molecules, the remaining 
analyte molecules must remain completely in the mobile phase until they move farther down the 
column where active sites are available. This decreases the retention time for that portion of the 
analyte molecules, resulting in peak fronting. If a smaller amount of sample was introduced or if 
a larger split ratio was employed, the peak should become more symmetric. The fragmentation of 
gabapentin and the interpretation of its mass spectrum was discussed in chapter 1. On-fiber 
derivatization was unsuccessful for gabapentin with both BSTFA + 1% TMCS and DMF-DMA. 
No chromatographic peak for the TMS derivative was formed, and while the DMAM derivative 
was formed, the derivatization was incomplete. 
 
Figure 49. TIC of 14.4 µg of gabapentin in 24 µL of methanol. 
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Lorazepam 
 Underivatized lorazepam produced a single chromatographic peak in TV-SPME, as it did 
in liquid injection, that was identified with a NIST mass spectral library search. The optimum 
extraction temperature was 150℃. The fragmentation of lorazepam and the interpretation of its 
mass spectrum was discussed in chapter 1. On-fiber derivatization was unsuccessful for gabapentin 
with both BSTFA + 1% TMCS and DMF-DMA. No chromatographic peaks were formed for either 
lorazepam derivative. 
 
Figure 50. TIC of 24 µg of lorazepam in 24 µL of methanol. 
 
Vigabatrin 
 Only the dehydration product of vigabatrin was detected by TV-SPME without 
derivatization. No derivatives were detected with BSTFA + 1% TMCS or DMF-DMA. 
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Pregabalin 
 Pregabalin was detected in the underivatized form by TV-SPME. Pregabalin was not 
successfully derivatized with BSTFA + 1% TMCS or DMF-DMA on-fiber. 
 
Figure 51. TIC of 24 µg of pregabalin in 24 µL of methanol. 
 
Clorazepate 
 Clorazepate was not detected by TV-SPME in either the underivatized or derivatized 
forms, with BSTFA + 1% TMCS or DMF-DMA. 
 
 As shown in tables 6-8, derivatization generally improved chromatographic performance. 
For example, though the peak symmetry for amphetamine worsened by 129% due to column 
overloading with TFAA derivatization, separation efficiency increased by 156% and sensitivity 
increased by 1%. The peak symmetry for methamphetamine improved by 10% with TFAA 
derivatization while separation efficiency increased by 5,552% and sensitivity increased by 16%. 
The peak symmetry for 2C-I improved by 9% with TFAA derivatization separation efficiency 
increased by 45% and sensitivity decreased by 3%. The peak symmetry for 25I-NBOMe worsened 
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by 9% with TFAA derivatization while separation efficiency increased by 62% and sensitivity 
increased by 36%. The peak symmetry for 25I-NBOH improved by 57% with TFAA derivatization 
while separation efficiency increased by 5,944% and sensitivity increased by 16%. The peak 
symmetry for psilocin improved by 73% with BSTFA + 1% TMCS derivatization while separation 
efficiency increased by 200% and sensitivity increased by 31%. 
Table 6. Comparing asymmetry factors for underivatized drugs and their derivatives 
Drug Underivatized Derivatized 
Amphetamine 1.28 0.46 
Methamphetamine 0.60 0.64 
2C-I 0.26 0.33 
25I-NBOMe 0.31 0.25 
25I-NBOH 1.14 0.94 
Psilocin 2.58 0.58 
 
Table 7. Comparing separation efficiency (number of theoretical plates) for underivatized drugs 
and their derivatives 
Drug Underivatized (/106) Derivatized (/106) 
Amphetamine 0.25 0.64 
Methamphetamine 0.046 2.6 
2C-I 2.2 3.2 
25I-NBOMe 2.1 3.4 
25I-NBOH 0.091 5.5 
Psilocin 1.7 5.1 
 
Table 8. Comparing sensitivity (peak area) for underivatized drugs and their derivative 
Drug Underivatized (/107) Derivatized (/107) 
Amphetamine 7.7 7.8 
Methamphetamine 2.5 2.9 
2C-I 65 63 
25I-NBOMe 110 150 
25I-NBOH 1.4 16 
Psilocin 16 21 
 
Conclusion 
 TV-SPME proved to be an effective technique for analyzing controlled substances both 
with and without on-fiber derivatization. Amphetamine, 2C-I, 25I-NBOMe, psilocin, gabapentin, 
lorazepam, and pregabalin were all identified by TV-SPME without derivatization. 
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methamphetamine and 25I-NBOH were also identified without derivatization, but 
chromatographic performance was unsatisfactory. To our knowledge, this is the first report of 
identification of 25I-NBOH by GC-MS. 
 Derivatization with TFAA was chosen for the amine and hydroxylamine drugs. TFAA 
derivatization was effective for amphetamine, methamphetamine, 2C-I, and 25I-NBOMe, and 
successful but incomplete for 25I-NBOH. On-fiber derivatization with TFAA proved ineffective 
for psilocin and psilocybin, producing no derivatives for either. 
 Derivatization with BSTFA + 1% TMCS was chosen for the zwitterionic drugs as well as 
GHB, psilocin, and psilocybin. DMF-DMA derivatization was attempted for the zwitterionic 
drugs. On-fiber derivatization was unsuccessful for all the zwitterionic drugs chosen, with either 
BSTFA + 1% TMCS or DMF-DMA. On-fiber derivatization of gabapentin with DMF-DMA was 
incomplete, with most of the drug remaining in the underivatized state. The other zwitterions 
produced no derivative with either derivatization agent. 
Psilocybin produced no derivative using on-fiber derivatization with BSTFA + 1% TMCS. 
On-fiber derivatization of psilocin produced a psilocin-TMS derivative which dominated the 
chromatogram despite a small chromatographic peak for underivatized psilocin still present. GHB 
proved an excellent candidate for on-fiber derivatization with BSTFA + 1% TMCS. As expected, 
GHB could not be detected by GC-MS in the underivatized form. On-fiber derivatization, 
however, produced a single chromatographic peak for GHB di-TMS with strong signal. 
  
53 
 
 
 
Table 9. Summary of results for liquid injection and TV-SPME methods. + indicates the formation 
of a single chromatographic peak which could be unambiguously identified. 0 indicates that 
multiple peaks formed, and – indicates that no peak formed. 
Drug Liquid Injection TV-SPME 
Amphetamine + + 
Amphetamine + TFAA + + 
Methamphetamine + + 
Methamphetamine + TFAA + + 
Ephedrine + + 
Ephedrine + TFAA + 0 
2C-I + + 
2C-I + TFAA + + 
25I-NBOMe + + 
25I-NBOMe + TFAA + + 
25I-NBOH - 0 
25I-NBOH + TFAA - 0 
Psilocin + + 
Psilocin + BSTFA + 1% TMCS + + 
Psilocybin + - 
Psilocybin + BSTFA + 1% TMCS - - 
GHB - - 
GHB + BSTFA + 1% TMCS + + 
Gabapentin + + 
Gabapentin + BSTFA + 1% TMCS - - 
Gabapentin + DMF-DMA + 0 
Lorazepam + + 
Lorazepam + BSTFA + 1% TMCS + - 
Lorazepam + DMF-DMA - - 
Vigabatrin - - 
Vigabatrin + BSTFA + 1% TMCS + - 
Vigabatrin + DMF-DMA + - 
Pregabalin - + 
Pregabalin + BSTFA + 1% TMCS 0 - 
Pregabalin + DMF-DMA 0 - 
Clorazepate  - - 
Clorazepate + BSTFA + 1% TMCS + - 
Clorazepate + DMF-DMA - - 
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While not ideal for all analytes, TV-SPME with on-fiber derivatization could be a powerful 
technique for amine and hydroxylamine controlled substances as well as GHB. The technique 
could increase analyst efficiency by reducing sample preparation time for these types of analytes. 
The method is particularly well-suited to the analysis of GHB since the drug cannot be analyzed 
by GC-MS in its native state. The technique has been tested on “realistic” seized drug samples, 
including GHB samples, the results of which are presented in chapter 3. The potential exists to 
remove sample preparation entirely by analyzing drugs of abuse in their native state (e.g. white 
powder) using on-fiber derivatization. This possibility is explored in chapter 4. 
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CHAPTER 3. REALISTIC SAMPLES AND SOLID DRUG 
DERIVATIZATION 
Introduction 
 As discussed in Chapter 2, on-fiber derivatization has proven effective for many drugs as 
standards in aprotic solvents. Suspected controlled substances submitted to a laboratory, however, 
are often impure. The ability of the on-fiber derivatization method to handle realistic samples 
needed to be tested. To that end, four different kinds of realistic samples were designed – “street 
meth”, GHB-spiked beverages, hallucinogenic mushrooms, and solid drug powders.  
The first realistic sample - referred to as “street meth” and containing methamphetamine, 
ephedrine, and caffeine - was meant to simulate an impure methamphetamine sample 
manufactured in a clandestine laboratory and adulterated. In a methamphetamine seizure, 
identification of cutting agents, precursors, and synthetic pathways employed can be of 
investigative and potentially legislative interest. There are two prominent synthetic pathways that 
use ephedrine or pseudoephedrine as a precursor. The Emde method, which is a two-step reduction 
of ephedrine to methamphetamine via chloroephedrine (figure 52), is very common in Asia35-37. 
Direct reduction of ephedrine or pseudoephedrine to methamphetamine via the Nagai (“red P”) 
method using hydriodic acid and red phosphorus (figure 53)36-38 or via the “Nazi/Birch” method 
using lithium metal and ammonia (figure 54)39 is much more common in the United States. 
Impurities in the final product, including unreacted starting materials, intermediates, and 
byproducts or the ratios of these impurities have been used to determine the synthetic route utilized 
in the manufacture of methamphetamine samples36-37, 40. 
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Figure 52. The synthetic pathway from ephedrine to methamphetamine via the Emde method35. 
 
 
Figure 53. The synthetic pathway from ephedrine to methamphetamine via the Nagai method38. 
 
 
Figure 54. The synthetic pathway from ephedrine to methamphetamine via the “Nazi/Birch” 
method39. 
 
 The second type of realistic sample was beverages spiked with gamma-hydroxybutyric 
acid (GHB). GHB is used in drug-facilitated sexual assaults (DFSA) because it incapacitates 
victims, induces memory loss, and does not persist in the human body41. The drug can be 
surreptitiously administered to a victim’s drink, in which case a forensic scientist may receive a 
beverage suspected of containing GHB. This drug is impossible to analyze “as is” by GC-MS due 
to its acidity (pKa 4.7), high polarity, low volatility, and high solubility in aqueous solution. GHB 
and gamma-butyrolactone (GBL) interconvert in aqueous solutions42-43. Additionally, GHB can 
be converted to GBL in the high heat of the GC inlet, further complicating its analysis28. 
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Figure 55. The conversion of GHB to GBL via dehydration (ΔHo= 4.5±0.2 kJ/mol)44. 
 
Though the most common instrumental techniques for detecting GHB are GC-MS28, 45-51 
and liquid chromatography-mass spectrometry52, GHB has also been identified using Raman 
spectroscopy53-54, infrared spectroscopy55, and nuclear magnetic resonance spectroscopy56-57. All 
routine GC-MS methods and many LC-MS methods for identifying GHB require derivatization 
following an involved extraction procedure. This makes beverages spiked with GHB ideal as 
realistic samples with which to test the on-fiber derivatization method. 
Hallucinogenic mushrooms were the third type of realistic sample chosen. Mushrooms of 
the genus Psilocybe have been used as parts of religious rituals and ceremonies for centuries, but 
Wasson was the first to publish on their hallucinogenic effects in 195758. In 1958, Hoffman et al. 
identified and extracted the two main psychotropic alkaloids, psilocybin and psilocin59. Both 
compounds are now schedule I controlled substances in the United States. In some jurisdictions 
the two are treated the same under the law while in others there is a distinction, in which case an 
analyst must have a method that can distinguish between the two alkaloids. This can prove difficult 
as psilocybin readily dephosphorylates to psilocin in the heated inlet of a gas chromatograph. 
Derivatization in the solution phase with BSTFA + 1% TMCS is routinely employed to prevent 
this dephosphorylation but has so far proven unsuccessful for on-fiber derivatization, as discussed 
in chapter 2. Even so, on-fiber derivatization with BSTFA + 1% TMCS was tested on 
hallucinogenic mushroom samples donated by the Indiana State Police. The dried mushrooms were 
analyzed without any extraction procedures. 
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 The final type of realistic sample tested was solid drug powders. As discussed in Chapter 
2, on-fiber derivatization performed in aprotic solvents has proven effective in decreasing sample 
preparation time for problematic drugs of abuse.  We also explored the possibility of analyzing 
solid powders directly with on-fiber derivatization, which would eliminate the use of any solvent. 
To test this possibility, one drug from each class explored in this thesis was analyzed as a powder. 
Methamphetamine was chosen to represent secondary amines, 2C-I was chosen to represent 
primary amines, gabapentin was selected to represent zwitterions, GHB was selected to represent 
hydroxycarboxylic acids, and ephedrine was selected to represent hydroxy phenylethylamines. 
 
Experimental 
Materials 
Methamphetamine HCl, ephedrine HCl, and dimethyl formamide dimethyl acetal (DMF-
DMA) were purchased from Sigma-Aldrich (St. Louis, Missouri). 4-iodo-2,5-dimethoxy-β-
phenethylamine (2C-I) hydrochloride, gamma-hydroxybutyric acid (GHB), and gabapentin were 
purchased from Cayman Chemical (Ann Arbor, Michigan). HPLC grade methanol, Optima 
acetonitrile, trifluoroacetic anhydride (TFAA), and N,O-bis(trimethylsilyl)trifluoroacetamide with 
1% trimethylchlorosilane (BSTFA + 1% TMCS) were purchased from Thermo Fisher Scientific 
(Waltham, Massachusetts). Polydimethyl siloxane solid phase microextraction fibers, 100 µm film 
thickness, were purchased from Supelco (Bellefonte, Pennsylvania). Coke® and rum were 
purchased from a local supermarket. 
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Simulated “Street Meth” 
 To create a simulated “street meth” sample, 11 mg of methamphetamine, 2 mg of 
ephedrine, and 28 mg of caffeine were mixed together. This mixture was dissolved in 28 mL of 
methanol to create a solution with the following concentrations for each drug: 0.39 mg/mL 
methamphetamine, 0.07 mg/mL ephedrine, and 1.0 mg/ mL caffeine. An aliquot of 240 µL of this 
solution was placed into a 20-mL headspace vial. The methanol was evaporated to dryness and 
reconstituted in 18 µL of acetonitrile for analysis. On-fiber derivatization was accomplished by 
exposing the SPME fiber to the headspace of a vial containing TFAA for five minutes before 
moving it to the sample, which was vaporized by heating at 90℃. After an extraction time of 10 
minutes, the fiber was moved to the inlet of the GC for desorption at 250℃. 
 
GHB-Spiked Beverages 
According to the United States Drug Enforcement Agency, the average dose of GHB is 
between 1 and 5 grams41. The drug users’ forum Erowid lists the range for a “strong dose” of GHB 
as 2-4 g60. A typical mixed drink is 7 fluid ounces or 207 mL. Therefore, if the smallest “strong 
dose” of GHB, 2 mg, were dissolved in a typical mixed drink with a volume of 207 mL, the 
resulting solution would have a GHB concentration of 9.7 mg/mL. Erring on the conservative side, 
spiked beverage samples were created by adding 250 µL of beverage to 2 mg of solid GHB and 
allowing to dissolve, creating an 8 mg/mL solution. 2.5 µL of the resulting solution was then added 
to a 20 mL headspace vial for analysis. Due to its success derivatizing GHB in solutions of 
acetonitrile and dichloromethane, as seen in chapter 2, BSTFA + 1% TMCS was chosen for use in 
beverage samples as well. Because BSTFA reacts with water, it was necessary to saturate the fiber 
with the derivatization agent so that it could react with the water and leave enough BSTFA free to 
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react with the GHB. This was accomplished by increasing the time that the fiber spent in the 
headspace of the derivatization vial. Times of 10, 20, 30, 40, 50, and 60 were tested. After the fiber 
was saturated with derivatization agent, it was moved to the sample vial, where the sample was 
vaporized by heating to 60℃. After an extraction time of 10 minutes, the fiber was moved to the 
inlet of the GC for desorption at 250℃. 
 
Hallucinogenic Mushrooms 
 A few dried stems and a dried cap from the mushrooms were placed in a 20-mL headspace 
vial for analysis. A fresh vial of BSTFA + 1% TMCS was prepared by placing several drops of 
the derivatization agent in the bottom of a 20-mL headspace vial. For analysis, a PDMS SPME 
fiber was exposed to the headspace of the derivatization vial for 50 minutes then moved to the 
headspace of the sample vial, which was heated at 120℃. After 10 minutes extraction time, the 
fiber was moved to the inlet of the GC, heated at 250℃, for desorption. 
 
Solid Drug Samples 
 One milligram of powder was placed in a 20-mL headspace vial for analysis. A fresh vial 
of derivatization agent was prepared daily by placing several drops of derivatization agent in the 
bottom of a 20-mL headspace vial. For analysis, a PDMS SPME fiber was exposed to the 
headspace of the derivatization vial for 5 minutes, then moved to the headspace of the sample vial, 
which was heated at 60℃ for GHB, 90℃ for methamphetamine and ephedrine, or 120℃ for 2C-
I and gabapentin. After 10 minutes extraction time, the fiber was moved to the inlet of the GC, 
heated at 250℃, for desorption. 
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GC-MS Parameters 
An Agilent 6890N GC coupled to an Agilent 5975 inert Mass Selective Detector with an 
attached Gerstel PAL RTC MultiPurpose Sampler (MPS) was used for all experiments. The GC 
column was an Agilent Technologies DB-5MS column with a length of 30 m, a 0.250 mm inner 
diameter, and a 0.25 µm film thickness. Straight inlet liners of 1.2 mm inner diameter from SGE 
Analytical Science were used. 
The inlet temperature was set to 250°C and operated in split mode with a 15:1 split ratio. 
The initial oven temperature of 60°C was held for one minute, then the temperature was ramped 
at 15°C/min to 280°C where it was held for three minutes. A constant flow of 2.5 mL/min of 
hydrogen was maintained. The source was kept at 230°C and the quadrupoles were kept at 150°C. 
A scan range of m/z 40- m/z 550 was used, with a solvent delay of 2 minutes. 
 
Results 
Simulated “Street Meth” 
 Using the method parameters outlined in chapter 2, the concentration of ephedrine in the 
sample was too low. The sample volume was therefore increased from 24 µL to 240 µL of the 
methanol solution. With this larger sample size, the ephedrine derivative, the methamphetamine 
derivative, and caffeine were all detected. However, the signal for the ephedrine derivative was 
weaker than that of two unidentified peaks in the chromatogram. Though this is not ideal, the 
ephedrine was detected, so investigative leads about the precursor and synthetic pathway could 
still be obtained. 
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Figure 56. “street meth” chromatogram showing the methamphetamine derivative and caffeine 
(left) and zoomed in to show the ephedrine derivative (right). 
 
GHB-Spiked Beverages 
 The time that the SPME fiber was exposed to the headspace of the BSTFA vial was tested 
from 10 minutes to 60 minutes to determine the shortest time necessary to saturate the fiber enough 
to produce a clear chromatographic peak for the derivative. The sample for the tests was 2.5 µL of 
water spiked with GHB. Though the highest signal was obtained for 60 minutes, it was determined 
that 50 minutes was adequate time to produce a clear peak. It would be ideal to achieve this 
increased signal while simultaneously decreasing analysis time by dosing the fiber with 
derivatization agent more quickly. Possible solutions to achieve this will be discussed in chapter 
4. 
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Figure 57. Plot of the GHB signal (measured by the area under the curve for EIC m/z 233) vs the 
time spent by the SPME fiber in headspace of the derivatization vial. 
 
 Once the fiber saturation time was determined, the method was used to analyze 3 different 
beverages spiked with GHB: Coke®, rum, and a rum & Coke® mixed drink. Each beverage sample 
was first analyzed without derivatization to illustrate that the GHB could not be detected this way, 
then with on-fiber derivatization using BSTFA + 1% TMCS to assess the utility of the method. 
Blank samples of the beverage that had not been spiked with GHB were also tested, both with and 
without derivatization, to ensure that GHB was not detected from the beverages themselves. GHB 
was not detected in unspiked beverages, nor in spiked beverages without derivatization. GHB was 
clearly identified in all three spiked beverages using on-fiber derivatization. 
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Figure 58. Stacked chromatograms for Coke® spiked with 8 mg/mL GHB, analyzed without 
derivatization (B) and with on-fiber derivatization using BSTFA + 1% TMCS (A) 
 
 
Figure 59. Stacked chromatograms for rum spiked with 0.8 mg/mL GHB, analyzed without 
derivatization (B) and with on-fiber derivatization using BSTFA + 1% TMCS (A) 
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Figure 60. Stacked chromatograms for rum spiked with 8 mg/mL GHB, analyzed without 
derivatization (B) and with on-fiber derivatization using BSTFA + 1% TMCS (A) 
 
Hallucinogenic Mushrooms 
 The dried mushroom caps and stems were not subjected to any extraction before analysis. 
No psilocybin, psilocin, or derivative of either was detected. These results indicate that on-fiber 
derivatization is not suitable for mushroom samples. Because previous work with pure psilocybin 
on-fiber derivatization has also yielded negative results, it is possible that this drug is incompatible 
with this method.  Changes to the method must be made to accommodate psilocybin, such as 
different fiber chemistry, an even longer derivatization time, or a different derivatization agent. 
 
Solid Drugs 
 Methamphetamine, GHB, and ephedrine produced single chromatographic peaks for their 
derivatives when analyzed as solid powders. Derivatization of gabapentin was incomplete, with 
the presence of a large chromatographic peak split into two peaks corresponding to underivatized 
gabapentin. The derivatization of 2C-I was complete, suggesting that TFAA could be used as an 
2 3 4 5 6 7 8 9 10
T
IC
TIME (min)
B
A
GHB di-TMS
66 
 
effective derivatization agent for analysis of primary amines as solid powders. However, the 
chromatogram showed not only 2C-I TFA, but also a species corresponding to 2C-I TFA that had 
lost the iodine atom. Attempts to stop this effect by manipulating extraction temperature were 
unsuccessful. 
 
Figure 61. Chromatograms for A: methamphetamine TFA and B: methamphetamine 
underivatized 
 
 
Figure 62. Chromatograms for A: GHB di-TMS and B: GHB underivatized 
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Figure 63. Chromatograms of A: ephedrine TFA and B: ephedrine underivatized 
 
 
Figure 64. Chromatograms of A: gabapentin DMAM and B: gabapentin underivatized 
 
Conclusion 
 On-fiber derivatization has been proven to be an effective and useful tool for analysis of 
realistic seized drug samples, particularly for amines and GHB. On-fiber derivatization was 
unsuccessful for hallucinogenic mushrooms in this study, however, and requires further research. 
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TV-SPME with on-fiber derivatization using TFAA was able to identify all three components of 
a simulated impure sample of methamphetamine, detecting methamphetamine and ephedrine as 
the TFA derivatives and caffeine underivatized. This method was applied to the identification of 
GHB in mixed drinks, where it excelled. Despite the presence of protic solvents, on-fiber 
derivatization with BSTFA + 1% TMCS resulted in unambiguous identification of GHB in 
samples of water, Coke®, rum, and a 2:1 mixture of rum and Coke®. Powdered controlled 
substances were also analyzed with on-fiber derivatization, in their solid forms. The results were 
promising for all drug classes that were analyzed successfully by on-fiber derivatization as 
solutions. This discovery greatly improves the utility of the technique, as controlled substances are 
most often encountered in their solid forms in forensic science laboratories. The application of this 
technique to beverage samples and solid drug powders is of most interest, as these applications 
represent a significant decrease in sample preparation. 
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CHAPTER 4. FUTURE WORK 
Toxicology 
The work presented in this thesis makes up the bulk of a large project on the derivatization 
of controlled substances by GC-MS focused on developing TV-SPME on-fiber derivatization 
techniques. The next and final phase of the project is the demonstration of the technique’s utility 
for toxicological samples. The technique has already been proven effective for GHB as well as 
phenethylamine and phenethylamine-derived drugs in aprotic solvents and as solid powders. In the 
case of GHB, the technique has also been demonstrated to be remarkably effective in aqueous and 
alcoholic solutions. Adaptation of the technique to urine samples therefore should be 
straightforward. The challenges will be in assessing the technique’s flexibility, or its ability to 
derivatize and identify the many metabolites of drugs of interest, and its sensitivity when working 
with the much lower concentrations of drugs and metabolites in toxicological samples as compared 
to seized drug samples. 
Methamphetamine represents a best-case-scenario drug for adaptation from seized drug to 
toxicological samples because methamphetamine itself is excreted in urine, and its primary 
metabolite is amphetamine3, 21, both of which yielded strongly positive results for on-fiber 
derivatization. The zwitterionic drugs will present a much greater challenge. Gabapentin, 
vigabatrin, and pregabalin are largely excreted in urine with little metabolism61-63 while 
clorazepate is metabolized to nordiazepam64 and lorazepam is metabolized primarily to its 
glucuronide and several minor metabolites65, though clorazepate and lorazepam are both excreted 
in urine as well. In general, the need to detect and identify metabolites as well as parent drugs will 
complicate the toxicological adaptation of the method, though many of the metabolites should also 
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be amenable to derivatization. It is not advisable to attempt toxicological testing with the 
zwitterions, however, until a satisfactory method for their detection in organic solutions with on-
fiber derivatization is developed. 
The conditions for the identification of GHB in mixed drinks are the most closely 
analogous to toxicological samples that are presented in this thesis. Toxicological samples are 
generally aqueous solutions just as the mixed drink samples were. Therefore, the same saturation 
of the fiber with derivatization agent will be necessary. This method has already proven effective 
for GHB analysis and provides a great starting point for toxicological analyses. GHB presents 
additional obstacles in toxicological analyses, however. Firstly, greater than 95% of GHB taken 
orally is metabolized to carbon dioxide and water and the rest is rapidly eliminated, becoming 
undetectable in blood and urine after 12 hours66-67. GHB is a naturally-occurring neurotransmitter 
and a metabolite of the neurotransmitter gamma-aminobutyric acid (GABA)68 and is therefore 
present in the human body at low levels even without consumption of GHB. This is evidenced by 
preliminary data collected by Kymeri Davis in our laboratory which highlights yet another 
application of on-fiber derivatization. Kymeri placed a human hair in a headspace vial, analyzed 
it via on-fiber derivatization with BSTFA + 1% TMCS, and detected endogenous GHB. Her data 
is shown in figures 65 and 66, below. As one would expect, the signal for the GHB di-TMS 
derivative in the hair sample was much lower than that for spiked beverages. The chromatographic 
peak for GHB di-TMS is not visible in the TIC (figure 65), but can be seen in the extracted ion 
chromatogram for m/z 233 (figure 66). 
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Figure 65. TIC of human hair derivatized with BSTFA + 1% TMCS (Data courtesy of Kymeri 
Davis). 
 
 
Figure 66. EIC for m/z 233 of human hair derivatized with BSTFA + 1% TMCS (Data courtesy 
of Kymeri Davis) 
 
A study to determine the concentration of GHB naturally present in biological fluids found 
that GHB was present in 670 urine samples in the range of 34-575 µg/dL and in 240 blood samples 
in the range of 17-151 µg/dL51. The same study suggests endogenous GHB cutoff levels of 1000 
µg/dL in urine and 500 µg/dL in blood. Any toxicological methods require quantitation, and this 
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is especially true of GHB analyses because of its natural presence in biological fluids. The on-fiber 
derivatization method for GHB detection presented in this thesis could be easily adapted to a 
quantitative technique by creating calibrants of varying concentrations and adding an internal 
standard to each of them and to the sample of unknown concentration. Deuterated GHB (GHB-
D6) is recommended for the internal standard.  
 
Beverage Samples 
A quantitative technique is necessary for GHB not only in toxicological samples but in 
drinks as well. This is because GHB is naturally occurring at low levels in some beverages. A 
study from 2005 reported that of 50 alcoholic beverages tested in the UK, GHB was only detected 
in those beverages which were made from fermenting grapes. It was detected in red wine vermouth 
at 8.2 mg/L, Sherry at 9.7 mg/L, red wine at 4.1-21.4 mg/L, and white wine at “<3-9.6 mg/L”69. A 
study published in 2017, however, detected GHB in beverages unrelated to the fermentation of 
grapes. This study tested both alcoholic and non-alcoholic beverages and found GHB in tonic 
water at 130-180 ng/mL, in rum at 100-150 ng/mL, in vodka at 160-190 ng/mL, in tequila at 210-
270 ng/mL, in fruit juice from 300-500 ng/mL, in beer at 330-430 ng/mL, in red wine at 9300-
12000 ng/mL, and in white wine at 2500-3200 ng/mL70. Luckily, these concentrations are well 
below pharmacologically active doses. Even so, this highlights the importance of using 
quantitative methods for the analysis of GHB not just in biological fluids but in beverages as well.  
 
Method Improvement 
 Though the on-fiber derivatization with TV-SPME method presented in this thesis showed 
great promise and utility, several drug derivatizations which were amenable to liquid injection 
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methods were not amenable or were unsatisfactory for SPME methods. Most notable of these were 
the zwitterionic anti-epileptics (gabapentin, vigabatrin, lorazepam, pregabalin, and clorazepate) 
and psilocybin, for which derivatization was incomplete or no derivative was detected at all. The 
incomplete derivatization of gabapentin suggests that there is hope for complete derivatization at 
least for gabapentin and potentially for the rest of the zwitterions as well. Additional 
experimentation should be done to attempt to obtain complete derivatization for as many of these 
drugs as possible. For example, longer time in the headspace of the derivatization vial could be 
tested, introducing more derivatization agent to the sample. Additional extraction time could also 
be explored, allowing the reaction more time to take place. It is also possible that DMF-DMA is 
not volatile enough at room temperature for a sufficient amount of the agent to volatilize and 
adsorb to the fiber. Derivatizations using this agent could potentially be improved by heating the 
agent when exposing the fiber, if this is the case. Furthermore, as discussed in chapter 1, larger 
silylation reagents such as MTBSTFA are slower to form but more stable, and therefore may be 
more successful in derivatizing these difficult analytes. Though the ephedrine TFA derivative was 
detected as a single chromatographic peak, the sensitivity achieved was far less than ideal in TV-
SPME, so this reaction could also be improved.  
 It is desirable to shorten sample analysis time as much as possible. This is particularly true 
of the beverage sample method, which takes nearly an hour and a half per sample due to the 50 
minutes necessary to saturate the fiber with derivatization agent. As discussed in chapter 3, 
significantly better sensitivity could be attained by allowing the fiber to stay in the derivatization 
agent vial even longer, but this is not desirable. Therefore, methods to saturate the fiber more 
quickly should be explored. One potential solution is to heat the derivatization vial, thereby 
increasing the amount of the agent in the headspace. Unfortunately, this method was initially 
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attempted and proven disadvantageous for TFAA derivatization, as the heated TFAA rapidly 
deteriorated the septum of the vial cap, which coupled with the increased pressure within the vial 
caused the septum to rupture. Heating may be compatible with vials of BSTFA + 1% TMCS or 
DMF-DMA, however. An interesting idea is to immerse the fiber in a solution of derivatization 
agent in an aprotic solvent for a short time. The concentration of derivatization agent, the solvent 
chosen, and the immersion time would all need to be investigated, but this change could have the 
potential to drastically reduce analysis time. 
 A few clarifications are also of interest. For instance, the electron ionization (EI) spectrum 
of 25I-NBOH is relatively unknown, as this drug is not typically detected by GC-MS. The 
spectrum shows an [M-2]+ ion, the origin of which was hypothesized in chapter 2. It is 
hypothesized that perhaps the amine and hydroxyl hydrogens, being close together, leave the 
molecule as H2. This hypothesis could be tested using deuterium labeling. Deuterium (D) is a 
stable isotope of hydrogen which has one neutron in addition to the one proton of normal hydrogen 
(protium). Therefore, deuterium is one mass unit heavier than hydrogen. If the hydroxyl and amine 
hydrogens of 25I-NBOH were replaced with deuterium, the molecular weight would be increased 
from 413 to 415. If our hypothesis about these two hydrogens leaving together was true, we would 
expect to see an [M-4]+ ion in place of the [M-2]+, which would still be at m/z 411. We would also 
expect to see a m/z 108 fragment rather than an m/z 107 and all other fragments in the mass 
spectrum would remain at the same m/z value.  
Throughout this thesis and in other works utilizing a similar technique, the technique has 
been referred to as “on-fiber” derivatization, implying that the derivatization reaction takes place 
directly on the fiber substrate. However, it is unclear whether the reaction indeed takes place 
directly on the fiber or if it really takes place in the headspace surrounding the fiber. Testing this 
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may prove difficult. One could dose one fiber with derivatization agent and expose the dosed fiber 
and a second clean fiber to the headspace of an analyte vial and test the fibers for the presence of 
the derivative. The issue with this approach is that some of the derivatization agent itself could 
leave the dosed fiber and adsorb to the second fiber, confounding the results. While this distinction 
is of academic interest and certainly worth exploring, it does not affect the effectiveness of the 
method. 
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